Shots:

• The P-III OLE study involves assessing of Dupixent (300mg) + SOC in 2-282 adults/ adolescents with mod.-to-sev. asthma prior participated in a controlled Dupixent clinical trial- including the pivotal P-IIb DRI (24wks.) and P-III QUEST (52wks.) trials in patients with mod.-to-sev. asthma and the P-III VENTURE (24wks.) trial in patients with severe OCS-dependent asthma
• The P-III OLE study results demonstrated the safety & efficacy profile observed in previous Dupixent trials were maintained for up to 3yrs. i.e-  improvement in lung function by 13-22% @96wks.- patients maintained a low rate of severe asthma attacks- AE rates (76-88%) and will be presented at 2020 ERS International Congress
• Dupixent is a mAb inhibiting the signaling of the IL-4 & IL-13 proteins and is the only biologic  to demonstrate sustained improvements in lung function and asthma exacerbations across a broad patient population with type 2 inflammation

­ Ref: Sanofi | Image: News Medical